Medhini Group: Pharmaceutical bridge between Malaysia and India

THIS year marks a very important year for India-Malaysia bilateral relations as it signifies 65 years of diplomatic relations between the two nations.

Medhini Group Sdn Bhd (MG), established in Feb 2020 is proud to represent two major Indian Biotech and Pharmaceutical ecosystem builders in Malaysia and for neighbouring countries. MOU’s were signed in Pune and Mumbai last June between Medhini Group with DD Enterprise (DDE) and Modular Mobile Facility (MMF).

The MOU’s signify an important step for MG to use Malaysia as the launch pad to address the region’s demand for drug manufacturing capacity uplift programs by partnering with world-class equipment manufacturers and service providers in this sector.

Indian Prime Minister Narendra Modi has aptly described India as the “pharmacy of the world”, sending much-needed medicines to a number of countries during the COVID-19 pandemic.

Over the years, India’s famed pharmaceutical companies have created path-breaking innovations, especially in getting life-saving medicines at the most affordable prices to regions that need them the most. Given the extensive experience Indian firms have in this sector, naturally, they became the first choice for MG to leverage and explore value-for-money products and services for our clients.

DDE has vast experience in process engineering and skid fabrication ranging for more than 44 years operating from Pune serving major biotech and vaccine manufacturers globally. As a faster and more economical alternative to traditional stick-built process systems, DDE has designed and manufactured smarter, modular process skids for their global clientele. With more than 2500 systems delivered, MG & DDE will be in a prime position to support drug manufacturers by bringing their products to markets much faster, quicker validation, and enabling them to save on critical costs. In Malaysia, their process system is installed in Biocon for the manufacturing of Insulin since 2014.

MMF on the other hand is a fully owned subsidiary of Pharma Access Pvt. Ltd., (PA) an international EPC company that is transforming the pharmaceutical engineering sector through its integrated turnkey solutions for more than 20 Years.

MMF was conceived with the notion to provide a power of certainty to its customers by putting modern technology to work in the field of Pharma, Vaccines, and Biotech Facilities.

 This Plug and play highly customizable sterile facility has the capacity for 10 million Units of Vials & Pre-filled Syringes and Cartridges within an area (footprint) of 200 sq. mts. Modular manufacturing unit enables faster turnaround at a competitive cost delivering drugs quicker to those in need as compared to traditional in-situ construction which is often limited by local expertise to build and commission such facilities.

Medhini Group, a member of the UNGCMYB is committed to bringing sustainable solutions for the high-tech industries in APAC operating out of Malaysia. MG to date has provided engineering and construction management services to various MNCs to set up their greenfield manufacturing plants and brownfield expansion projects. These collaborations will further strengthen MG’s value proposition to enhance capacity building in the high-tech manufacturing sector.

Strategically, these partnerships will tap into India’s position as the number one vaccine manufacturer globally and use Malaysia as the gateway to regional countries. Indian companies have invested more than 2.6 billion USD for various projects in Malaysia which including Biocon (a major client for MG), the first overseas manufacturing and research plant in Johor Malaysia.

MG has recently completed masterplan design for Insulet, a medical device manufacturing plant, and subsequently will manage the design and construction of the cleanroom to manufacture devices within a GMP environment is regulated by USFDA. The greenfield project will be located in SilC Iskandar Puteri Johor and produce the company’s Omnipod Insulin Management System and consist of 400,000 square feet of manufacturing space. Insulet plans to invest approximately $200 million over five years and hire more than 1500 full-time employees once the facility is operating at full capacity. Besides Insulet and Biocon, MG is currently supporting clients in the Life Sciences sector namely Nutrition Technologies, Exyte for Dexcom as well as semiconductor clients.


Share This Post

More To Explore